{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:44:57Z","timestamp":1794865497742,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50981-6","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:16:59Z","timestamp":1777421819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["3D-QSAR and free energy landscape analysis for predicting novel JAK3 inhibitors in rheumatoid arthritis therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Fatemeh","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3022-2507","authenticated-orcid":false,"given":"Maryam","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"10055","key":"50981_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388 (10055), 2023\u20132038 (2016).","journal-title":"Lancet"},{"key":"50981_CR2","doi-asserted-by":"crossref","unstructured":"Jang, S., Kwon, E. J. & Lee, J. J. Rheumatoid arthritis: Pathogenic roles of diverse immune cells. Int. J. Mol. Sci. 23(2). (2022).","DOI":"10.3390\/ijms23020905"},{"key":"50981_CR3","doi-asserted-by":"crossref","unstructured":"Lin, Y. J., Anzaghe, M. & Sch\u00fclke, S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 9(4). (2020).","DOI":"10.3390\/cells9040880"},{"key":"50981_CR4","doi-asserted-by":"publisher","first-page":"686155","DOI":"10.3389\/fimmu.2021.686155","volume":"12","author":"J Huang","year":"2021","unstructured":"Huang, J. et al. Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. Front. Immunol. 12, 686155 (2021).","journal-title":"Front. Immunol."},{"issue":"17","key":"50981_CR5","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1016\/j.bmc.2018.04.005","volume":"26","author":"Y Yin","year":"2018","unstructured":"Yin, Y. et al. Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors. Bioorg. Med. Chem. 26 (17), 4774\u20134786 (2018).","journal-title":"Bioorg. Med. Chem."},{"key":"50981_CR6","doi-asserted-by":"publisher","first-page":"112148","DOI":"10.1016\/j.ejmech.2020.112148","volume":"191","author":"L Shu","year":"2020","unstructured":"Shu, L. et al. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors. Eur. J. Med. Chem. 191, 112148 (2020).","journal-title":"Eur. J. Med. Chem."},{"issue":"Suppl 1","key":"50981_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.31138\/mjr.31.1.100","volume":"31","author":"CM Lin","year":"2020","unstructured":"Lin, C. M., Cooles, F. A. & Isaacs, J. D. Basic Mechanisms of JAK Inhibition. Mediterr. J. Rheumatol. 31 (Suppl 1), 100\u2013104 (2020).","journal-title":"Mediterr. J. Rheumatol."},{"key":"50981_CR8","doi-asserted-by":"publisher","first-page":"6633251","DOI":"10.1155\/2023\/6633251","volume":"2023","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Combination of Synonymous and Missense Mutations in JAK3 Gene Contributes to Severe Combined Immunodeficiency in One Child. Hum. Mutat. 2023, 6633251 (2023).","journal-title":"Hum. Mutat."},{"issue":"33","key":"50981_CR9","doi-asserted-by":"publisher","first-page":"eabo4363","DOI":"10.1126\/sciadv.abo4363","volume":"8","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing \u03b3c cytokine\u2013related JAK-STAT signal. Sci. Adv. 8 (33), eabo4363 (2022).","journal-title":"Sci. Adv."},{"issue":"18","key":"50981_CR10","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1016\/j.bmc.2018.08.005","volume":"26","author":"H Hamaguchi","year":"2018","unstructured":"Hamaguchi, H. et al. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. Bioorg. Med. Chem. 26 (18), 4971\u20134983 (2018).","journal-title":"Bioorg. Med. Chem."},{"issue":"10387","key":"50981_CR11","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King, B. et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet 401 (10387), 1518\u20131529 (2023).","journal-title":"Lancet"},{"issue":"11","key":"50981_CR12","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1136\/annrheumdis-2015-208901","volume":"75","author":"MC Genovese","year":"2016","unstructured":"Genovese, M. C., Yang, F., \u00d8stergaard, M. & Kinnman, N. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. Ann. Rheum. Dis. 75 (11), 1979\u20131983 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"50981_CR13","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1038\/s41598-018-23569-y","volume":"8","author":"H Pei","year":"2018","unstructured":"Pei, H. et al. Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis. Sci. Rep. 8 (1), 5273 (2018).","journal-title":"Sci. Rep."},{"key":"50981_CR14","doi-asserted-by":"crossref","unstructured":"Fang, Z. et al. CS12192, a novel JAK3\/JAK1\/TBK1 inhibitor, synergistically enhances the anti-inflammation effect of methotrexate in a rat model of rheumatoid arthritis. Int. J. Mol. Sci. 23(21). (2022).","DOI":"10.3390\/ijms232113394"},{"issue":"16","key":"50981_CR15","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1021\/acs.jmedchem.5b00710","volume":"58","author":"L Tan","year":"2015","unstructured":"Tan, L. et al. Development of Selective Covalent Janus Kinase 3 Inhibitors. J. Med. Chem. 58 (16), 6589\u20136606 (2015).","journal-title":"J. Med. Chem."},{"key":"50981_CR16","doi-asserted-by":"crossref","unstructured":"Lin, X., Li, X. & Lin, X. A review on applications of computational methods in drug screening and design. Molecules 25(6). (2020).","DOI":"10.3390\/molecules25061375"},{"issue":"12","key":"50981_CR17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2174\/1568026618666180813152921","volume":"18","author":"X Wang","year":"2018","unstructured":"Wang, X., Song, K., Li, L. & Chen, L. Structure-Based Drug Design Strategies and Challenges. Curr. Top. Med. Chem. 18 (12), 998\u20131006 (2018).","journal-title":"Curr. Top. Med. Chem."},{"key":"50981_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-4939-9752-7_2","volume":"2053","author":"LHS Santos","year":"2019","unstructured":"Santos, L. H. S., Ferreira, R. S. & Caffarena, E. R. Integrating Molecular Docking and Molecular Dynamics Simulations. Methods Mol. Biol. 2053, 13\u201334 (2019).","journal-title":"Methods Mol. Biol."},{"issue":"23","key":"50981_CR19","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.2174\/09298673113209990001","volume":"20","author":"A Lavecchia","year":"2013","unstructured":"Lavecchia, A. & Di Giovanni, C. Virtual screening strategies in drug discovery: a critical review. Curr. Med. Chem. 20 (23), 2839\u20132860 (2013).","journal-title":"Curr. Med. Chem."},{"issue":"9","key":"50981_CR20","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1080\/07391102.2023.2222839","volume":"42","author":"A Faris","year":"2024","unstructured":"Faris, A., Hadni, H., Ibrahim, I. M. & Elhallaoui, M. In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives. J. Biomol. Struct. Dynamics. 42 (9), 4817\u20134833 (2024).","journal-title":"J. Biomol. Struct. Dynamics"},{"issue":"10","key":"50981_CR21","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.3390\/ijms23105437","volume":"23","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Design of rational JAK3 inhibitors based on the parent core structure of 1, 7-dihydro-dipyrrolo [2, 3-b: 3\u2032, 2\u2032-e] pyridine. Int. J. Mol. Sci. 23 (10), 5437 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"50981_CR22","doi-asserted-by":"publisher","first-page":"101464","DOI":"10.1016\/j.imu.2024.101464","volume":"45","author":"M Prieto","year":"2024","unstructured":"Prieto, M., Ni\u00f1o, A., Acosta-Guzm\u00e1n, P. & Guevara-Pulido, J. Design and synthesis of a potential selective JAK-3 inhibitor for the treatment of rheumatoid arthritis using predictive QSAR models. Inf. Med. unlocked. 45, 101464 (2024).","journal-title":"Inf. Med. unlocked"},{"issue":"3","key":"50981_CR23","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s11030-024-10958-x","volume":"29","author":"K Banerjee","year":"2025","unstructured":"Banerjee, K., Chandrasekar, B., Sathish, S., Sohn, H. & Madhavan, T. Computational drug repositioning for IL6 triggered JAK3 in rheumatoid arthritis using FDA database. Mol. Diversity. 29 (3), 2049\u20132061 (2025).","journal-title":"Mol. Diversity"},{"issue":"1","key":"50981_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/co500122h","volume":"17","author":"M Gehringer","year":"2015","unstructured":"Gehringer, M., Forster, M. & Laufer, S. A. Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition. ACS Comb. Sci. 17 (1), 5\u201310 (2015).","journal-title":"ACS Comb. Sci."},{"issue":"24","key":"50981_CR25","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1021\/jm1004286","volume":"53","author":"ME Flanagan","year":"2010","unstructured":"Flanagan, M. E. et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 53 (24), 8468\u20138484 (2010).","journal-title":"J. Med. Chem."},{"issue":"6","key":"50981_CR26","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/07391102.2017.1326319","volume":"36","author":"M Abbasi","year":"2018","unstructured":"Abbasi, M., Sadeghi-Aliabadi, H. & Amanlou, M. 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold. J. Biomol. Struct. Dyn. 36 (6), 1463\u20131478 (2018).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"4","key":"50981_CR27","doi-asserted-by":"publisher","first-page":"2200186","DOI":"10.1002\/minf.202200186","volume":"42","author":"MS Bahia","year":"2023","unstructured":"Bahia, M. S. et al. A comparison between 2D and 3D descriptors in QSAR modeling based on bio-active conformations. Mol. Inf. 42 (4), 2200186 (2023).","journal-title":"Mol. Inf."},{"key":"50981_CR28","doi-asserted-by":"publisher","first-page":"1545791","DOI":"10.3389\/fphar.2025.1545791","volume":"16","author":"D Xie","year":"2025","unstructured":"Xie, D. et al. 3D-QSAR, design, molecular docking and dynamics simulation studies of novel 6-hydroxybenzothiazole-2-carboxamides as potentially potent and selective monoamine oxidase B inhibitors. Front. Pharmacol. 16, 1545791 (2025).","journal-title":"Front. Pharmacol."},{"key":"50981_CR29","unstructured":"SYBYL-X 2.0 (Tripos Inc. St. Louis U. SYBYL-X 2.0 (Tripos Inc. St. Louis, USA)."},{"issue":"4","key":"50981_CR30","doi-asserted-by":"publisher","first-page":"e3223","DOI":"10.1002\/cem.3223","volume":"34","author":"G D\u00f6rg\u0151","year":"2020","unstructured":"D\u00f6rg\u0151, G., P\u00e9ter Hamadi, O., Varga, T. & Abonyi, J. Mixtures of QSAR models: Learning application domains of p K predicto rs. J. Chemom. 34 (4), e3223 (2020).","journal-title":"J. Chemom."},{"issue":"9","key":"50981_CR31","doi-asserted-by":"publisher","first-page":"105863","DOI":"10.1016\/j.arabjc.2024.105863","volume":"17","author":"Y-K Zhang","year":"2024","unstructured":"Zhang, Y-K. et al. Design and evaluation of piperidine carboxamide derivatives as potent ALK inhibitors through 3D-QSAR modeling, artificial neural network and computational analysis. Arab. J. Chem. 17 (9), 105863 (2024).","journal-title":"Arab. J. Chem."},{"key":"50981_CR32","unstructured":"Maestro, S. & New York, L. L. C. NY, Maestro,Schr\u00f6dinger, LLC, New York, NY (2015)."},{"key":"50981_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132, 19\u201325 (2015).","journal-title":"SoftwareX"},{"issue":"13","key":"50981_CR34","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J. Comput. Chem. 25 (13), 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"issue":"1","key":"50981_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1756-0500-5-367","volume":"5","author":"AW Sousa da Silva","year":"2012","unstructured":"Sousa da Silva, A. W. & Vranken, W. F. ACPYPE - AnteChamber PYthon Parser interfacE. BMC Res. Notes. 5 (1), 367 (2012).","journal-title":"BMC Res. Notes"},{"issue":"8","key":"50981_CR36","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jmgm.2009.01.006","volume":"27","author":"E Papaleo","year":"2009","unstructured":"Papaleo, E., Mereghetti, P., Fantucci, P., Grandori, R. & De Gioia, L. Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: the myoglobin case. J. Mol. Graph. Model. 27 (8), 889\u2013899 (2009).","journal-title":"J. Mol. Graph. Model."},{"key":"50981_CR37","doi-asserted-by":"crossref","unstructured":"Lanka, G., Banerjee, S., Regula, S., Adhikari, N. & Ghosh, B. Pharmacophore modeling, 3D-QSAR, and MD simulation-based overture for the discovery of new potential HDAC1 inhibitors. J. Biomol. Struct. Dyn. 1\u201324. (2024).","DOI":"10.1080\/07391102.2024.2429020"},{"issue":"5","key":"50981_CR38","doi-asserted-by":"publisher","first-page":"5348","DOI":"10.3390\/ijms13055348","volume":"13","author":"L Ouyang","year":"2012","unstructured":"Ouyang, L. et al. Combined structure-based pharmacophore and 3D-QSAR studies on phenylalanine series compounds as TPH1 inhibitors. Int. J. Mol. Sci. 13 (5), 5348\u20135363 (2012).","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"50981_CR39","doi-asserted-by":"publisher","first-page":"e101079","DOI":"10.1371\/journal.pone.0101079","volume":"9","author":"JS Chauhan","year":"2014","unstructured":"Chauhan, J. S. et al. QSAR-based models for designing quinazoline\/imidazothiazoles\/pyrazolopyrimidines based inhibitors against wild and mutant EGFR. PloS one. 9 (7), e101079 (2014).","journal-title":"PloS one"},{"issue":"7","key":"50981_CR40","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/ph17070889","volume":"17","author":"M Lorca","year":"2024","unstructured":"Lorca, M. et al. 2D\/3D-QSAR model development based on a quinoline pharmacophoric core for the inhibition of Plasmodium falciparum: an in silico approach with experimental validation. Pharmaceuticals 17 (7), 889 (2024).","journal-title":"Pharmaceuticals"},{"issue":"3","key":"50981_CR41","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s11030-023-10650-6","volume":"28","author":"B Yazdani","year":"2024","unstructured":"Yazdani, B. et al. Discovery of novel direct small-molecule inhibitors targeting HIF-2\u03b1 using structure-based virtual screening, molecular dynamics simulation, and MM-GBSA calculations. Mol. Diversity. 28 (3), 1203\u20131224 (2024).","journal-title":"Mol. Diversity"},{"key":"50981_CR42","doi-asserted-by":"crossref","unstructured":"Jolliffe, I. T. & Cadima, J. Principal component analysis: a review and recent developments. Philos. Trans. R. Soc. A Math. Phys. Eng. Sci. 374(2065), 20150202 (2016).","DOI":"10.1098\/rsta.2015.0202"},{"key":"50981_CR43","unstructured":"Shaw, D. E. et al. (eds) Millisecond-scale molecular dynamics simulations on Anton. In Proceedings of the conference on high performance computing networking, storage and analysis; (2009)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50981-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50981-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50981-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:49:02Z","timestamp":1782773342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50981-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50981"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50981-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19835"}}